The fear of going out of business before getting a drug submitted to regulators is one that a couple of European biotechs have had to face up to this week.
The news that Sweden's Isofol Medical AB is planning to go into liquidation and 4D Pharma Plc of the UK has just avoided a similar fate has again demonstrated that biotech in Europe can be a brutal business.
First up, Isofol is to call an extraordinary general meeting (EGM) to discuss paying a cash dividend and liquidating the...
With China’s Hengrui reporting successful Phase III data for its dual GLP-1/GIP agonist, licensee Kailera is readying plans to demonstrate better efficacy than current obesity drugs.
Big pharma is increasingly looking east to restock its pipelines, a process that is helping to forge a new generation of mid-sized R&D-based companies in China and is reflected in their stock price performance.
Pharma company financial guidance emerged largely unscathed from a first quarter punctured by a weakening US dollar and threats of import tariffs on drugs. With other pressures either already evident or on the horizon, guidance revisions may be unavoidable.
